

Mumbai, 30th October, 2017

**Wockhardt Q2FY18 Net Sales at Rs.1,022 crore,
 grew by 15% Quarter-on-Quarter**

	Q2-FY18	Q1-FY18	Q2-FY17	H1FY18	H1FY17	FY17
	Jul - Sep 2017	Apr - Jun 2017	Jul - Sep 2016	Apr - Sep 2017	Apr - Sep 2016	Apr - Mar 2017
	INR Cr	INR Cr	INR Cr	INR Cr	INR Cr	INR Cr
Sales	1,022	891	1,065	1,913	2,156	4,015
EBITDA before R&D	84	(7)	199	77	392	423
EBITDA % to Sales	8.2%	-0.8%	18.7%	4.0%	18.2%	10.5%
R&D	77	72	99	149	207	397
R&D % to Sales	7.5%	8.1%	9.3%	7.8%	9.6%	9.9%
EBITDA	7	(79)	100	(72)	185	26
EBITDA Margins %	0.7%	-8.9%	9.4%	-3.7%	8.6%	0.6%
PBT before exceptional item	(28)	(121)	26	(149)	33	(247)
Exceptional item ^[1]	-	(358)	-	(358)	-	-
PBT after exceptional item	(28)	(479)	26	(507)	33	(247)
Profit After Tax	(3)	(410)	17	(413)	33	(196)
PAT Margins %	-0.3%	-46.0%	1.6%	-21.6%	1.5%	-4.9%
EPS	(0.3)	(37.1)	1.5	(37.4)	3.0	(17.7)

[1] During the quarter ended June 30, 2017, the commercial litigation between the Company and two of its subsidiaries in UK in relation to a supply contract for a drug with Cephalon Inc, an affiliate of Teva Pharmaceuticals USA, Inc. before the High Court in London, UK, was settled. Pursuant to this settlement the ongoing litigation stands closed.

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 2nd Quarter for Financial Year 2018, today.

Business review for the 2nd quarter and half year ended 30th September, 2017:

Marked improvement in sales performance during the quarter was achieved with a growth of 15% Q-o-Q after subdued few quarters that were mostly owing to Brexit in UK, genericisation of some of the products in US, demonetisation and introduction of GST in India.

While on-going expenses on remedial measures continued to impact the profitability, the Company's focus on cost containments and rationalisation has started giving its intended positive impact thereby significantly reducing losses quarter on quarter. However, the focus in strategic R&D initiatives of the Company continues in spite of the fact that they are expensed off.

India Business:

Grew by 49% Q-o-Q and by 5% in Q2FY18 over Q2FY17. Four (4) New Products were launched during the quarter.

Emerging Market Business of the Company grew by 2% in Q2FY18 over Q2FY17.

UK Business in GBP term remained flat in Q2FY18 vs Q2FY17. The Company received 1 new approval in UK market in H1FY18.

The company's continued pursuit in creating strong Intellectual Property (IP) base resulted into filing of 31 patents during the Quarter ended 30th September, 2017 taking the cumulative filings to 2,955. The company was granted 22 patents during the quarter and now totally holds 584 patents.

The company made 1 new filling in Q2FY18 and received 1 new approval taking the cumulative ANDA's pending for approval at 78. 1 tentative ANDA approval received in US.

Quarter ended 30th September, 2017

International Business contributed 56% of the total revenues during the Q2FY18.

Research & Development expenditure during the quarter was at Rs.77 crore (8% to sales) and including capital expenditure is at 11% to sales.

Capital expenditure of Rs 63 crore was incurred in Q2FY18.

US Business stands at 15% of the Global Revenues and grew by 4% Q-o-Q mainly on account of New Products approval by US FDA.

The Irish Business remained flat in Euro terms and de grew by 3% in INR terms in Q2FY18.

Half Year ended 30th September, 2017

Consolidated revenue for H1FY18 was Rs.1,913 crore.

International Business contributed 61% of the Total Revenues during the H1FY18.

The company continued to focus in Research & Development with half yearly spent at Rs.149 crore (8% to sales) and including capital expenditure is at 11% to sales for Half year ended FY18.

Capital expenditure of Rs.114 crore was incurred in H1FY18.

India Business de grew by 11% in H1FY18 compared to H1FY17 mostly on account of GST introduction. 8 New Products were launched in H1FY18.

Emerging Market Business grew by 6% in H1FY18 compared to H1FY17.

US Business stands at 16% of the Global Revenues.

The Irish Business grew by 11% in Euro terms and grew by 3% in INR terms in H1FY18.

About Wockhardt :

Wockhardt is a Global Pharmaceutical and Biotech company employing over 10,000 people and 27 nationalities with presence in USA, UK, Ireland, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 61% of its global revenues coming from international businesses. Wockhardt is home to 600 plus scientists, of whom 70 plus are doctorates. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes – 2 of them are Gram Negative and 3 Gram Positive. Wockhardt's entire Anti-infective portfolio particularly addresses the specific bacterial organism where resistances are high and breakthrough antibiotics are needed